ivabradine has been researched along with Heart Failure, Systolic in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 54 (90.00) | 24.3611 |
| 2020's | 6 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ameri, P; Brunetti, ND; Canepa, M; Castagno, D; Correale, M; De Ferrari, GM; De Marzo, V; Porto, I; Tricarico, L; Zoccai, GB | 1 |
| Imamura, T; Kinugawa, K | 1 |
| Imamura, T; Izumida, T; Kinugawa, K | 1 |
| Cui, D; Li, J; Liu, G; Liu, K; Lou, D; Lu, S; Ma, S; Pang, X; Wang, J; Wang, X; Wu, S; Xie, X; Xue, L; Yang, Z; Ye, F; Yu, H; Zhang, Y; Zhong, M | 1 |
| Bocchi, EA; Lima, IGCV | 1 |
| Abdin, A; Batailler, C; Böhm, M; Borer, J; Ford, I; Komajda, M; Mahfoud, F; Slawik, J; Swedberg, K; Tavazzi, L | 1 |
| Anguita, M; Hidalgo, FJ | 1 |
| Sargento, L | 1 |
| Grimm, D; Hedegaard, ER; Simonsen, U; Thorup, L | 1 |
| Balsam, P; Lelonek, M; Opolski, G; Ozierański, K; Ponikowski, P; Wilkins, A | 1 |
| Dural, M; Iskenderov, K; Mert, GÖ; Mert, KU; Özen, A | 1 |
| Dahlström, U; Das, D; Ezekowitz, JA; Fu, M; Howlett, J; Lund, LH; Savarese, G | 1 |
| Eckman, PM | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; Maack, C; Moyne, A; Swedberg, K; Tavazzi, L | 1 |
| Foley, PWX; Zivlas, C | 1 |
| Bocchi, EA; Guimarães, GV; Rassi, S | 1 |
| Anguita, M; Carrasco, F; Castillo, JC; Hidalgo, F | 1 |
| Adena, MA; Hamann, G; Sindone, AP | 1 |
| Bonadei, I; Carubelli, V; Fabbricatore, D; Lombardi, CM; Metra, M; Pagnoni, M; Rossi, L; Sciatti, E; Vizzardi, E | 1 |
| Clements, JN; Meade, CM | 1 |
| Fragasso, G; Gemma, M; Godino, C; Margonato, A; Montanaro, C; Pinto, G; Salerno, A; Slavich, M; Spoladore, R; Tondi, L | 1 |
| Chow, SL; Depre, C; Page, RL | 1 |
| Lim, WY; Woldman, S | 1 |
| Abrahamsson, P; Böhm, M; Borer, JS; Ford, I; Kober, L; Komajda, M; Lloyd, SM; Metra, M; Swedberg, K; Tavazzi, L | 1 |
| Böhm, M; Reil, JC | 1 |
| Longo, S; Lousada, N; Palma dos Reis, R; Sargento, L; Satendra, M | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; Lainscak, M; Robertson, M; Swedberg, K; Tavazzi, L | 1 |
| Di Franco, A; Di Pasquale, P; Figliozzi, S; Lanza, GA; Parrinello, R; Salerno, Y; Sarullo, FM | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; Robertson, M; Swedberg, K; Tavazzi, L | 1 |
| dos Reis, RP; Longo, S; Lousada, N; Sargento, L; Satendra, M | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; Manolis, AJ; Robertson, M; Swedberg, K; Tavazzi, L | 1 |
| Bremont, C; Damy, T; Dubois-Rande, JL; Gallet, R; Guendouz, S; Gueret, P; Lim, P; Seemann, A; Ternacle, J | 1 |
| Bagriy, AE; Bagriy, EA; Malovichko, SI; Pricolota, AV; Pricolota, OA; Samoilova, OV; Schukina, EV | 1 |
| Alihanoglu, YI; Evrengul, H; Kaftan, HA; Ordu, S; Ozhan, H; Ozsoy, A; Tosun, M; Yildiz, BS | 1 |
| Böhm, M; Borer, JS; Camm, J; Ford, I; Komajda, M; Lainscak, M; Lloyd, SM; Reil, JC; Swedberg, K; Talajic, M; Tavazzi, L; Ukena, C | 1 |
| Karchik'ian, PO; Saĭganov, SA | 1 |
| Bocchi, EA; Böhm, M; Borer, JS; Ford, I; Komajda, M; Swedberg, K; Tavazzi, L | 1 |
| Borer, JS; Ford, I; Kielhorn, A; Pocock, SJ; Rogers, JK | 1 |
| Böhm, M; Borer, JS; Ford, I; Kindermann, I; Komajda, M; Lainscak, M; Maack, C; Robertson, M; Swedberg, K; Tavazzi, L | 1 |
| Pereira-Barretto, AC | 1 |
| Chan, PH; Huang, D; Lam, CC; Shea, PC; Siu, CW; Tse, HF; Yiu, KH | 1 |
| Nguyen, E; Weeda, ER; White, CM | 1 |
| Böhm, M; Borer, JS; Ewen, S; Ford, I; Komajda, M; Laufs, U; Lloyd, SM; Lopez-Sendon, J; Mahfoud, F; Ponikowski, P; Swedberg, K; Tavazzi, L | 1 |
| Böhm, M; Borer, JS; Ford, I; Komajda, M; Moyne, A; Swedberg, K; Tavazzi, L | 1 |
| Böhm, M; Borer, JS; Dorman, ED; Ford, I; Kansal, AR; Kielhorn, A; Komajda, M; Krotneva, S; Patel, HK; Tavazzi, L; Zheng, Y | 1 |
| Böhm, M; Borer, JS; Ford, I; Kansal, AR; Kielhorn, A; Komajda, M; Krotneva, S; Maya, J; Patel, HK; Tafazzoli, A; Tavazzi, L | 1 |
| Böhm, M; Borer, JS; Deedwania, PC; Kim, JB | 1 |
| Branscombe, N; Cowie, MR; Davies, A; Griffiths, A; Paracha, N; Sculpher, M | 1 |
| Teerlink, JR | 1 |
| Ceriani, E; Rusconi, AM | 1 |
| Böhm, M; Borer, JS; Chassany, O; Ekman, I; Ford, I; Komajda, M; Swedberg, K; Tavazzi, L | 1 |
| Abdulazizov, OSh; Diachuk, LI; Kiiakbaev, GK; Kobalava, ZhD; Moiseev, VS; Potapenko, AV | 1 |
| Böhm, M; Borer, J; Ford, I; Komajda, M; Robertson, M; Swedberg, K; Tavazzi, L | 1 |
| Francis, GS; Sarraf, M | 1 |
| Anker, SD; McMurray, JJ | 1 |
| Alings, M; Böhm, M; Borer, JS; Ford, I; Komajda, M; Lopez-de-Sa, E; Sendon, JL; Swedberg, K; Tavazzi, L | 1 |
| Málek, F | 1 |
9 review(s) available for ivabradine and Heart Failure, Systolic
| Article | Year |
|---|---|
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis.
Topics: Clinical Trials, Phase III as Topic; Heart Failure, Systolic; Humans; Ivabradine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Stroke Volume; Ventricular Dysfunction, Left | 2022 |
Ivabradine: Current and Future Treatment of Heart Failure.
Topics: Benzazepines; Cardiotonic Agents; Cyclic Nucleotide-Gated Cation Channels; Heart; Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Membrane Transport Modulators; Practice Guidelines as Topic; Stroke Volume | 2017 |
Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
Topics: Adrenergic beta-Antagonists; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Treatment Outcome; Ventricular Dysfunction, Left | 2018 |
Pharmacological management of chronic heart failure: old drugs, new drugs and new indications.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiovascular Agents; Chronic Disease; Digoxin; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Hydralazine; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists | 2013 |
Heart rate and heart failure: the role of ivabradine therapy.
Topics: Anti-Arrhythmia Agents; Benzazepines; Depression, Chemical; Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2013 |
Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.
Topics: Adrenergic beta-Antagonists; Benzazepines; Chronic Disease; Clinical Trials as Topic; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Stroke Volume | 2014 |
Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure, Systolic; Hospitalization; Humans; Ivabradine; Quality of Life; Treatment Outcome | 2016 |
Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.
Topics: Angina Pectoris; Benzazepines; Canada; Cardiovascular Diseases; Coronary Artery Disease; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Myocardial Infarction; Stroke Volume; Treatment Outcome | 2016 |
Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Coronary Artery Disease; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Mortality; Quality of Life; Treatment Outcome; Ventricular Function, Left | 2016 |
18 trial(s) available for ivabradine and Heart Failure, Systolic
| Article | Year |
|---|---|
Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure.
Topics: Benzazepines; Cardiovascular Agents; Delayed-Action Preparations; Double-Blind Method; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
Topics: Cardiovascular Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2018 |
Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial.
Topics: Argentina; Brazil; Cardiovascular Agents; Chagas Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Survival Rate; Treatment Outcome; Ventricular Function, Left | 2018 |
Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure.
Topics: Cardiovascular Agents; Cost-Benefit Analysis; Female; Health Care Costs; Heart Failure, Systolic; Humans; Ivabradine; Male; Quality of Life; Quality-Adjusted Life Years; Treatment Outcome | 2019 |
Risk following hospitalization in stable chronic systolic heart failure.
Topics: Aged; Aged, 80 and over; Benzazepines; Cardiovascular Agents; Chronic Disease; Disease Progression; Female; Follow-Up Studies; Heart Failure, Systolic; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Time Factors | 2013 |
Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Cardiotonic Agents; Chronic Disease; Female; Heart Failure, Systolic; Heart Rate; Humans; Incidence; Ivabradine; Male; Middle Aged; Multivariate Analysis; Placebos; Prognosis; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Risk Factors; Treatment Outcome | 2013 |
Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
Topics: Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Failure, Systolic; Humans; Ivabradine; Male; Middle Aged; Prognosis; Prospective Studies; Severity of Illness Index; Treatment Outcome; Ventricular Function, Left | 2014 |
Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.
Topics: Aged; Benzazepines; Blood Pressure; Cardiovascular Agents; Double-Blind Method; Female; Heart Failure, Systolic; Humans; Hypertension; Hypotension; Ivabradine; Male; Middle Aged; Prognosis; Systole; Treatment Outcome | 2014 |
Effects of ivabradine therapy on heart failure biomarkers.
Topics: Aged; Benzazepines; Biomarkers; CA-125 Antigen; Cardiovascular Agents; Cystatin C; Down-Regulation; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Stroke Volume; Time Factors; Treatment Outcome; Turkey; Ventricular Function, Left | 2015 |
Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Bisoprolol; Carbazoles; Cardiovascular Agents; Carvedilol; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure, Systolic; Hospitalization; Humans; Ivabradine; Male; Metoprolol; Middle Aged; Nebivolol; Propanolamines; Proportional Hazards Models; Treatment Outcome | 2015 |
Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients.
Topics: Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Numbers Needed To Treat; Proportional Hazards Models; Treatment Outcome | 2015 |
Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
Topics: Aged; Benzazepines; Cardiovascular Agents; Comorbidity; Cyclic Nucleotide-Gated Cation Channels; Double-Blind Method; Female; Follow-Up Studies; Global Health; Heart Failure, Systolic; Heart Rate; Humans; Incidence; Ivabradine; Male; Middle Aged; Myocardial Infarction; Pulmonary Disease, Chronic Obstructive; Survival Rate; Treatment Outcome | 2015 |
Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT.
Topics: Aged; Benzazepines; Cardiovascular Agents; Disease Progression; Double-Blind Method; Female; Heart Failure, Systolic; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Patient Readmission; Treatment Outcome | 2016 |
Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial.
Topics: Aged; Benzazepines; Cardiovascular Agents; Cost-Benefit Analysis; Female; Heart Failure, Systolic; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Models, Statistical; Quality of Life; Severity of Illness Index; Surveys and Questionnaires | 2017 |
Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzazepines; Cause of Death; Chronic Disease; Double-Blind Method; Female; Heart Failure, Systolic; Humans; Ivabradine; Male; Middle Aged; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2011 |
[Efficacy of ivabradin in combined treatment of patients with postinfarction systolic chronic cardiac failure].
Topics: Anti-Arrhythmia Agents; Benzazepines; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Treatment Outcome | 2011 |
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Topics: Adrenergic beta-Antagonists; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Global Health; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Prospective Studies; Sinoatrial Node; Survival Rate; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study.
Topics: Benzazepines; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Female; Heart Failure, Systolic; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Secondary Prevention; Treatment Outcome | 2012 |
33 other study(ies) available for ivabradine and Heart Failure, Systolic
| Article | Year |
|---|---|
Doppler Echocardiography-Guided Heart Rate Modulation Therapy Using Ivabradine in a Patient with Systolic Heart Failure.
Topics: Aged; Echocardiography, Doppler; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Stroke Volume; Ventricular Function, Left | 2022 |
Efficacy of Doppler echocardiography-guided ivabradine therapy.
Topics: Benzazepines; Cardiovascular Agents; Echocardiography, Doppler; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Ventricular Function, Left | 2023 |
The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy: Quo Vadis?
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2022 |
Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
Topics: Benzazepines; Bradycardia; Cardiovascular Agents; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Stroke Volume; Treatment Outcome | 2023 |
Ivabradine in acute decompensated systolic heart failure.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine | 2017 |
Ivabradine in acute decompensated systolic heart failure.
Topics: Benzazepines; Cardiovascular Agents; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine | 2017 |
Adherence to the guidelines on the management of systolic heart failure in ambulatory care in Poland. Data from the international QUALIFY survey.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Disease Management; Female; Guideline Adherence; Heart Failure, Systolic; Humans; Ivabradine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Poland; Prospective Studies | 2017 |
Effects of heart rate reduction with ivabradine on the international ındex of erectile function (IIEF-5) in patients with heart failure.
Topics: Aged; Analysis of Variance; Benzazepines; Cardiovascular Agents; Echocardiography; Erectile Dysfunction; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Penile Erection; Pilot Projects; Quality of Life; Surveys and Questionnaires; Turkey | 2018 |
Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Benzazepines; Cardiovascular Agents; Clinical Trials as Topic; Eligibility Determination; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Patient Selection; Registries; Stroke Volume; Sweden; Time Factors; Treatment Outcome; Ventricular Function, Left | 2017 |
How Many Heart Failure Patients Might We SHIFT to a Lower Heart Rate?
Topics: Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Stroke Volume | 2017 |
Ivabradine - well tolerated in elderly patients with systolic heart failure.
Topics: Aged; Benzazepines; Cardiovascular Agents; Heart Failure; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Treatment Outcome | 2017 |
Effect of Early Treatment With Ivabradine Plus Beta-blockers on Long-term Outcomes in Patients Hospitalized With Systolic Heart Failure.
Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Stroke Volume; Time Factors; Treatment Outcome | 2018 |
Effects of ivabradine on endothelial function, aortic properties and ventricular-arterial coupling in chronic systolic heart failure patients.
Topics: Aged; Aged, 80 and over; Aorta; Benzazepines; Cardiotonic Agents; Chronic Disease; Echocardiography; Endothelium, Vascular; Female; Heart Failure, Systolic; Heart Ventricles; Humans; Ivabradine; Male; Middle Aged; Vascular Stiffness; Ventricular Remodeling | 2018 |
Ivabradine for systolic heart failure.
Topics: Benzazepines; Cardiovascular Agents; Diastole; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Systole; Treatment Outcome | 2018 |
Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Cardiovascular Agents; Chronic Disease; Echocardiography; Female; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2018 |
Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure.
Topics: Aged; Ambulatory Care; Anti-Arrhythmia Agents; Benzazepines; Biomarkers; Drug Therapy, Combination; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Prospective Studies; Stroke Volume; Time Factors; Treatment Outcome; Up-Regulation; Ventricular Function, Left | 2013 |
SHIfT: Ivabradine's additional clinical benefits regardless of background beta-blocker dose.
Topics: Adrenergic beta-Antagonists; Benzazepines; Cardiovascular Agents; Drug Administration Schedule; Drug Therapy, Combination; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzazepines; Blood Pressure; Female; Heart Failure, Systolic; Heart Rate; Humans; Intensive Care Units; Ivabradine; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Time Factors | 2014 |
Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction.
Topics: Aged; Benzazepines; Cardiotonic Agents; Dobutamine; Drug Therapy, Combination; Female; Heart Failure, Systolic; Hemodynamics; Humans; Ivabradine; Male; Middle Aged; Pilot Projects; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2014 |
Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
Topics: Adrenergic beta-Antagonists; Aged; Benzazepines; Carbazoles; Cardiovascular Agents; Carvedilol; Drug Therapy, Combination; Exercise; Exercise Tolerance; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Propanolamines; Prospective Studies; Risk Factors; Ventricular Dysfunction, Left | 2015 |
Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
Topics: Aged; Benzazepines; Cardiovascular Agents; Electrocardiography, Ambulatory; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Prospective Studies | 2015 |
[Correction of sinus rate by inhibitors of If-channels in patients with acute decompensated heart failure].
Topics: Acute Disease; Aged; Benzazepines; Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Monitoring; Echocardiography; Exercise Test; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Middle Aged; Statistics as Topic; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Ivabradine in Severe Aortic Stenosis with Poor Left Ventricular Ejection Fraction.
Topics: Aged, 80 and over; Aortic Valve Stenosis; Benzazepines; Cardiac Catheterization; Cardiovascular Agents; Electrocardiography; Heart Failure, Systolic; Heart Rate; Heart Valve Prosthesis Implantation; Humans; Ivabradine; Male; Recovery of Function; Severity of Illness Index; Stroke Volume; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2015 |
Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.
Topics: Aged; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Female; Heart Failure; Heart Failure, Systolic; Hospitalization; Humans; Ivabradine; Male; Medication Adherence; Middle Aged; Mortality; Placebos; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2016 |
Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Budgets; Cardiovascular Agents; Drug Costs; Female; Heart Failure, Systolic; Humans; Insurance Claim Review; Insurance, Health; Ivabradine; Male; Medicare Part C; Middle Aged; Pharmacopoeias as Topic; Retrospective Studies; Standard of Care; United States; Young Adult | 2016 |
Financial impact of ivabradine on reducing heart failure penalties under the Hospital Readmission Reduction Program.
Topics: Benzazepines; Heart Failure; Heart Failure, Systolic; Hospitals; Humans; Ivabradine; Patient Readmission | 2017 |
Ivabradine in heart failure--no paradigm SHIFT…yet.
Topics: Aged; Benzazepines; Cardiovascular Agents; Female; Heart Failure, Systolic; Heart Rate; Hospitalization; Humans; Ivabradine; Male; Middle Aged; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome | 2010 |
[Patients with cardiovascular risk. SH/fT study: mortality rate reduced by a fourth].
Topics: Benzazepines; Cardiovascular Agents; Clinical Trials as Topic; Cyclic Nucleotide-Gated Cation Channels; Drug Therapy, Combination; Germany; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Multicenter Studies as Topic; Patient Admission; Survival Rate | 2010 |
Ivabradine added to guidelines-based therapy in systolic heart failure patients.
Topics: Benzazepines; Heart Failure, Systolic; Humans; Ivabradine; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2011 |
It is all about heart rate. Or is it?
Topics: Adrenergic beta-Antagonists; Benzazepines; Electrocardiography; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Sinoatrial Node; Ventricular Dysfunction, Left | 2012 |
Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials?
Topics: Benzazepines; Cardiotonic Agents; Female; Heart Failure, Systolic; Humans; Ivabradine; Male | 2012 |
[Effect of ivabradin on heart rate, left ventricular function a NT-proBNP concentration in patients with systolic chronic heart failure--case reports].
Topics: Adult; Aged; Benzazepines; Chronic Disease; Cyclic Nucleotide-Gated Cation Channels; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Natriuretic Peptide, Brain; Peptide Fragments; Ventricular Function, Left; Ventricular Remodeling | 2012 |
[Effect of ivabradine on heart rate, left ventricular function and levels of NT-proBNP in patients with chronic systolic heart failure--case reports].
Topics: Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Female; Heart Failure, Systolic; Heart Rate; Humans; Ivabradine; Male; Natriuretic Peptide, Brain; Peptide Fragments; Ventricular Function, Left | 2012 |